Sani nudge has developed a hand hygiene tool that prompts medical professionals to clean their hands more often. Courtesy of TMC

Sani nudge, a graduate of the TMCx healthcare accelerator's nineth cohort at Houston's Texas Medical Center, is getting a significant nudge from a new collaboration with a social-impact organization based in California.

Among more than 1,000 startups that were considered, Copenhagen, Denmark-based Sani nudge was chosen as one of nine participants in the Mistletoe Research Fellowship Startup Collaboration Program, sponsored by the Mistletoe Foundation. Three dozen researchers from seven universities also are taking part in the program.

Fresh off a $1.2 million funding round, Sani nudge's technology is an automated monitoring system aimed at helping healthcare workers bolster hygiene compliance and processes through insights from data and a feature that "nudges" healthcare workers to practice proper hand hygiene. Sani nudge created the technology in conjunction with Bispebjerg Hospital and Aarhus University Hospital, both in Denmark.

In the Mistletoe program, representatives of Sani nudge will work alongside four American researchers to improve the startup's technology, thereby providing hospitals with better data and tapping the researchers' expertise in engineering and robotics to come up with related healthcare platforms. Sani nudge employs 13 people in the U.S., Denmark, and Poland.

During tests in healthcare settings, the use of Sani nudge has resulted in a jump in hand hygiene compliance of as much as 200 percent and a reduction in infections of at least 29 percent, the company says. Several hospitals in Scandinavia are using the Sani nudge system.

Theis Jensen, CEO of Sani nudge, and Dr. Marco Bo Hansen, the chief customer officer, became acquainted with Mistletoe when they met Mark Castleman — a partner at the Mistletoe Inc. global-impact investment fund — during a startup and innovation tour of Texas organized by Capital Factory, a startup accelerator with locations in Houston, Austin, and Dallas.

The three men soon found common ground in a shared vision for reducing hospital-acquired infections and combating resistance to antibiotics. Both are costly, potentially fatal problems.

At any given time, 1 in 25 patients in the U.S. are fighting hospital-acquired infections, the U.S. Department of Health and Human Services says. "These infections lead to the loss of tens of thousands of lives," according to the department, "and cost the U.S. healthcare system billions of dollars each year."

Meanwhile, more than 2 million people in the U.S. are infected each year with antibiotic-resistant bacteria, and at least 23,000 people die as a result, according to the U.S. Centers for Disease Control and Prevention (CDC).

Sani nudge's participation in the Mistletoe program kicked off July 31 and August 1 at a workshop in Tokyo. For the next nine months, the Sani nudge group — led by Rebekah Alexander, the startup's in-house data expert — will team up with its four assigned researchers to advance the startup's wireless technology.

The researchers "will work with us over the following academic year to help us take the Sani nudge solution to the next level and enable hospitals to get even more detailed hand hygiene information that can eliminate hospital-acquired infections," Sani nudge wrote on its blog.

In June 2020, the next-level Sani nudge technology is scheduled to be presented to potential investors and academic researchers in Silicon Valley. Sani nudge says Mistletoe effort will strengthen its ties to the U.S. market and the academic research community.

"There are many opportunities within healthcare IoT that can help both patients and hospitals, and our system is designed to embrace these opportunities," Hansen says.

Hansen, a physician, says he'll be vigilantly advocating that his Sani nudge colleagues and the Mistletoe researchers keep hospital patients and staff in mind as Sani nudge moves forward with its innovations.

"We have to make sure that our solutions always generate value to the end users and can easily be used by the clinicians, infection preventionists, and hospital managers," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston cleantech, space startups named to World Economic Forum cohort

top honor

Two Houston-based startups have been selected to join the World Economic Forum's Technology Pioneers community.

The two-year program aims to help mission-driven, early-stage start-ups scale their innovations through multi-stakeholder initiatives, co-creating partnerships and other gatherings for community members. One-hundred startups are selected each year from around the globe, this year hailing from 23 countries and working in AI, energy, space, biotech markets and more.

Cleantech startup Vaulted Deep was one of 11 energy and climate companies to be named to the cohort. Julia Reichelstein and Omar Abou-Sayed founded the company in 2023. Its technology injects excess organic waste underground to remove carbon dioxide from the atmosphere.

Last year, Vaulted Deep inked a 12-year deal with Microsoft to remove up to 4.9 million metric tons of carbon dioxide from the environment.

The startup has earned several accolades in recent years, including a No. 3 spot on Fast Company’s list of the World’s Most Innovative Companies of 2026. It was also recently named to market intelligence and advisory firm Cleantech Group's annual Global Cleantech 100 list for a second year in a row.

"Waste management is one of the world's great invisible infrastructure systems ... The need for new infrastructure is growing as disposal challenges become more complex and regulations evolve. Vaulted is building the first new disposal pathway for organic waste in decades by putting it deep underground, permanently," the company shared in a LinkedIn post. "This year, we're joining the World Economic Forum's 2026 Tech Pioneers alongside innovators working on the many interconnected challenges shaping our future."

Houston-based Venus Aerospace was also selected to join the cohort, along with six other spacetech companies. The company was founded in 2020 by Sassie and Andrew Duggleby.

The startup specializes in next-generation rocket engine propulsion as a cleaner alternative to traditional combustion engines. The company's rotating detonation rocket engine (RDRE) burns fuel more efficiently and completed a successful high-thrust test flight last year. Venus says it’s the only company in the world that makes a flight-proven, high-thrust RDRE with a “clear path to scaled production.”

"Frontier technologies matter most when they expand what people, industries, and nations can do," Sassie Duggleby, co-founder and CEO of Venus, said in a news release. "For Venus, RDRE does not just represent a more efficient engine. It is a foundation for faster movement, more capable space systems, and new forms of connectivity across the planet. Being named a Technology Pioneer validates the potential of this technology to help shape a future where distance is less limiting."

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”